San Diego, CA -- (SBWIRE) -- 05/06/2015 -- A deadline is coming up on May 12, 2015 in the lawsuit filed for investors of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) over alleged securities laws violations by ACADIA Pharmaceuticals.

Investors who purchased shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) have certain options and there are strict and short deadlines running. Deadline: May 12, 2015. NASDAQ:ACAD stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

According to the complaint filed in the U.S. District Court for the Southern District of California the plaintiff alleges on behalf of purchasers of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) common shares between February 26, 2015 and March 11, 2015, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between February 26, 2015 and March 11, 2015 defendants made allegedly false and misleading statements and/or allegedly failed to disclose adverse facts regarding the timing of ACADIA Pharmaceuticals' submission of its New Drug Application ("NDA") to the FDA for NUPLAZID and that as a result of defendants' statements or omissions between February 26, 2015 and March 11, 2015, ACADIA Pharmaceuticals Inc. securities traded at allegedly artificially inflated prices, with its stock trading at prices above $45 per share.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) reported that its Total Revenue declined from $4.91 million in 2012 to $0.12 million in 2014 and that its respective Net Loss increased from $20.85 million to $92.47 million. Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) grew from $1.91 in November 2012 to as high as $46.48 per share on March 10, 2015.

On Wednesday, March 11, 2015, ACADIA Pharmaceuticals Inc announced that Uli Hacksell would retire immediately as both its CEO and a member of its board of directors. In another statement reported Wednesday, ACADIA Pharmaceuticals Inc announced that it would postpone the timing of its planned New Drug Application submission for Nuplazid to the second half of the year. ACADIA Pharmaceuticals Inc had originally planned to submit the application in the first quarter.

Shares of ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) declined to $29.45 per share on March 26, 2015.

Those who purchased shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com